Is CJC-1295 Legal? Status in 158 Countries (2026)

Anguilla Legal No Not Scheduled Not scheduled. General pharmaceutical law applies. Antigua and Barbuda Legal No Not Scheduled Not scheduled. General drug act applies. Aruba Legal No Unregistered Not specifically regulated. General drug act applies. Bahamas Legal No Unregistered Not specifically regulated. General drug act applies. Barbados Legal No Unregistered Not specifically regulated. General drug act applies. Bosnia and Herzegovina Legal No Not Registered Non-EU. Not registered. GHRH analog. WADA banned. Research-label available. British Virgin Islands Legal No Not Scheduled Not scheduled. General pharmaceutical law applies. Cayman Islands Legal No Unregistered Not specifically regulated. General drug act applies. Costa Rica Legal No Unregistered Not specifically regulated. General drug act applies. Curacao Legal No Unregistered Not specifically regulated. General drug act applies. Dominica Legal No Not Scheduled Not scheduled. General drug act applies. Dominican Republic Legal No Unregistered Not specifically regulated. General drug act applies. Georgia Legal No Not Registered Non-EU. Not registered. GHRH analog. WADA banned. Research-label available. Essentially unregulated. Grenada Legal No Not Scheduled Not scheduled. General drug act applies. Jamaica Legal No Unregistered Not specifically regulated. General drug act applies. Montenegro Legal No Not Registered Non-EU. Not registered. GHRH analog. WADA banned. Research-label available. Montserrat Legal No Not Scheduled Not scheduled. General pharmaceutical law applies. North Macedonia Legal No Not Registered Non-EU. Not registered. GHRH analog. WADA banned. Research-label available. Papua New Guinea Legal No Not Scheduled Not specifically regulated. No local market for GH secretagogues. No enforcement infrastructure for peptide imports. Samoa Legal No Not Scheduled Not regulated. No local market or enforcement. Serbia Legal No Not Registered Non-EU. Not registered as medicine. GHRH analog. WADA banned. Research-label available. Very low enforcement. St Kitts and Nevis Legal No Not Scheduled Not scheduled. General drug act applies. St Lucia Legal No Not Scheduled Not scheduled. General drug act applies. St Vincent and the Grenadines Legal No Not Scheduled Not scheduled. General drug act applies. Tonga Legal No Not Scheduled Not regulated. No local market or enforcement. Trinidad and Tobago Legal No Unregistered Not specifically regulated. General drug act applies. Turks and Caicos Legal No Not Scheduled Not scheduled. General pharmaceutical law applies. Ukraine Legal No Not Registered Non-EU. Not registered. GHRH analog. WADA banned. Research-label available. Very low enforcement on research chemicals. Vanuatu Legal No Not Scheduled Not regulated. No local market or enforcement. United Kingdom Research Only No Not Scheduled Not a controlled substance. GHRPs not specifically scheduled in UK unlike Australia. Legal for research. Algeria Grey Area No Unregistered Not specifically regulated. No domestic market. Import restrictions effectively prevent access — must be marketed in origin + third country first. Andorra Grey Area No Not Scheduled Not authorized by AMA. Unauthorized medicinal product. Angola Grey Area No Unregistered Not specifically regulated. No domestic market. Minimal enforcement. Argentina Grey Area No Unregistered Not specifically regulated. General pharma law applies. Bahrain Grey Area No Unregistered Not specifically regulated. Bangladesh Grey Area No Not Scheduled Not registered with DGDA. No local market for GH peptides. Belize Grey Area No Unregistered Not specifically regulated. General pharma law applies. Bolivia Grey Area No Unregistered Not specifically regulated. General pharma law applies. Bonaire Grey Area No Not Scheduled Not scheduled. Dutch medicines framework applies. Botswana Grey Area No Unregistered Not specifically regulated. No domestic market. Import without BoMRA permit illegal. Brazil Grey Area No Unregistered Not specifically regulated. General pharma law applies. Brunei Grey Area No Not Scheduled Not registered. Cannot be legally imported or sold. No specific GH peptide regulation. Bulgaria Grey Area No Not Scheduled / Unauthorized No EMA authorization. GHRH analog. WADA banned. Research-label available. Cambodia Grey Area No Unregistered Available through local peptide suppliers. Not specifically restricted. Cameroon Grey Area No Unregistered Not specifically regulated. No domestic market. Import without authorization illegal. Canada Grey Area No Not Scheduled (CDSA) Named in Health Canada seizure notices as unauthorized drug. No DIN. Cape Verde Grey Area No Unregistered Not specifically regulated. No domestic market. Chile Grey Area No Unregistered Not specifically regulated. General pharma law applies. Colombia Grey Area No Unregistered Not specifically regulated. General pharma law applies. Croatia Grey Area No Not Scheduled / Unauthorized No EMA authorization. GHRH analog. WADA banned. Research-label available. Cyprus Grey Area No Not Scheduled No marketing authorization in EU. Unauthorized medicinal product under EU pharmaceutical law. Democratic Republic of Congo Grey Area No Unregistered Not specifically regulated. No domestic market. Minimal enforcement. Ecuador Grey Area No Unregistered Not specifically regulated. General pharma law applies. Egypt Grey Area No Unregistered Not specifically regulated. El Salvador Grey Area No Unregistered Not specifically regulated. General pharma law applies. Estonia Grey Area No Not Scheduled / Unauthorized No EMA authorization. GHRH analog. WADA banned. Research-label available. Ethiopia Grey Area No Unregistered Not specifically regulated. No domestic market. Not a regulatory priority for EFDA. Fiji Grey Area No Unregistered Not registered. Growth hormone peptides not specifically addressed. French Guiana Grey Area No Unauthorized Medicine Not approved. French framework. Ghana Grey Area No Unregistered Not specifically regulated. No domestic market. Guatemala Grey Area No Unregistered Not specifically regulated. General pharma law applies. Guyana Grey Area No Unregistered Not specifically regulated. General pharma law applies. Honduras Grey Area No Unregistered Not specifically regulated. General pharma law applies. Hong Kong Grey Area No Unregistered Not specifically regulated. Hungary Grey Area No Not Scheduled / Unauthorized No EMA authorization. GHRH analog. WADA banned. Research-label available. Iceland Grey Area No WADA S2 (peptide hormones); unauthorized medicine WADA S2 classified (GHRH analog). Postal import prohibited. Luggage import restricted to 30 days with doctor certificate. India Grey Area No Unregistered Available from Indian pharmaceutical suppliers. Indonesia Grey Area No Unregistered Not specifically regulated. Iran Grey Area No Not Scheduled Not registered. No local market. Sanctions prevent import. Iraq Grey Area No Not Scheduled Not registered. No specific regulation. Could enter through unregulated import. Israel Grey Area No Unregistered Not specifically regulated. Ivory Coast Grey Area No Unregistered Not specifically regulated. No domestic market. Japan Grey Area No Unapproved Drug Unapproved GH peptide. Strict PMDA framework. Jordan Grey Area No Unregistered Not specifically regulated. Kenya Grey Area No Unregistered Not specifically regulated. No domestic market. Kuwait Grey Area No Unregistered Not specifically regulated. Laos Grey Area No Unregistered Not registered. Growth hormone peptides not specifically addressed. Latvia Grey Area No Not Scheduled / Unauthorized No EMA authorization. GHRH analog. WADA banned. Research-label available. Lebanon Grey Area No Not Scheduled Not registered. No local market. Enforcement weakened by crisis. Libya Grey Area No Unregistered Not specifically regulated. No domestic market. No drug scheduling system. Liechtenstein Grey Area No Not Scheduled No marketing authorization in EEA. Unauthorized medicinal product. Lithuania Grey Area No Not Scheduled / Unauthorized No EMA authorization. GHRH analog. WADA banned. Research-label available. Luxembourg Grey Area No Not Scheduled No marketing authorization in EU. Unauthorized medicinal product. Madagascar Grey Area No Unregistered Not specifically regulated. No domestic market. Malawi Grey Area No Unregistered Not specifically regulated. No domestic market. Malaysia Grey Area No Unregistered Not specifically regulated. Maldives Grey Area No Unregistered Not registered. Growth hormone peptides not specifically addressed. Malta Grey Area No Unauthorized Medicine Not authorized. GHRH analog not approved by EMA. Cannot be legally sold or imported for human use. Mauritius Grey Area No Unregistered Not specifically regulated. No domestic market. Mexico Grey Area No Unregistered Available at peptide clinics (Renovo, ResCore, Holistic Bio Spa). Commonly paired with Ipamorelin. Monaco Grey Area No Not Scheduled No marketing authorization. Unauthorized medicinal product under French/EU pharmaceutical law. Morocco Grey Area No Unregistered No AMM. Not specifically regulated. No domestic market for research peptides. Mozambique Grey Area No Unregistered Not specifically regulated. No domestic market. Myanmar Grey Area No Unregistered Available through drug shops if imported. No enforcement of restrictions. Namibia Grey Area No Unregistered Not registered. No domestic market. Nepal Grey Area No Unregistered Not registered. Hormones Category KHA but growth hormone peptides not specifically listed. Nicaragua Grey Area No Unregistered Not specifically regulated. General pharma law applies. Nigeria Grey Area No Unregistered Not specifically regulated. Not NAFDAC registered. No domestic market. Oman Grey Area No Unregistered Not specifically regulated. Pakistan Grey Area No Not Scheduled Not registered with DRAP. No local market for GH peptides. Panama Grey Area No Unregistered Available at anti-aging/wellness clinics. Paraguay Grey Area No Unregistered Not specifically regulated. General pharma law applies. Peru Grey Area No Unregistered Not specifically regulated. General pharma law applies. Philippines Grey Area No Unregistered Not specifically regulated. Qatar Grey Area No Unregistered Not specifically regulated. Romania Grey Area No Not Scheduled / Unauthorized No EMA authorization. GHRH analog. WADA banned. Research-label available. Low enforcement. Russia Grey Area No Unregistered Not officially registered but available. Rwanda Grey Area No Unregistered Not registered. No domestic market. Saba Grey Area No Not Scheduled Not scheduled. Dutch medicines framework applies. Saint Barthelemy Grey Area No Unauthorized Medicine Not approved. French pharma law applies. Saint Martin (French) Grey Area No Unauthorized Medicine Not approved. French pharma law applies. Senegal Grey Area No Unregistered Not registered. No domestic market. Seychelles Grey Area No Unregistered Not registered. Growth hormone peptides not specifically addressed. Sint Eustatius Grey Area No Not Scheduled Not scheduled. Dutch medicines framework applies. Sint Maarten Grey Area No Not Scheduled Not scheduled. Dutch medicines framework applies. Slovakia Grey Area No Not Scheduled / Unauthorized No EMA authorization. GHRH analog. WADA banned. Research-label available. Slovenia Grey Area No Not Scheduled / Unauthorized No EMA authorization. GHRH analog. WADA banned. Research-label available. South Africa Grey Area No Unregulated Not specifically scheduled by SAHPRA. Growth hormone releasing peptides not individually listed in SA schedules (unlike Australia). Available from SA research peptide vendors. Clinics offer CJC-1295/Ipamorelin protocols. Note: actual HGH (somatotropin) IS Schedule 5. South Korea Grey Area No Unregistered Not specifically regulated. Sri Lanka Grey Area No Unregistered Not registered. Growth hormone peptides not approved by reference authorities. Suriname Grey Area No Unregistered Not specifically regulated. General pharma law applies. Taiwan Grey Area No Unregistered Not specifically regulated. Tanzania Grey Area No Unregistered Not TMDA registered. Import would require permit. Thailand Grey Area No Unregistered Available at anti-aging clinics in Bangkok, Phuket, Chiang Mai. Tunisia Grey Area No Unregistered No MA. Not specifically regulated. No domestic market. Turkey Grey Area No Unregistered Not specifically regulated. Uganda Grey Area No Unregistered Not specifically regulated. No domestic market. United States Grey Area No Not Scheduled Removed from Category 2 prohibited list Sept 2024 after nominators withdrew. NOT cleared for compounding — under PCAC review. Cannot be legally compounded pending review outcome. Uruguay Grey Area No Unregistered Not specifically regulated. General pharma law applies. US Virgin Islands Grey Area No Not Scheduled Same as US. Removed from Category 2 Sept 2024. Under PCAC review. Venezuela Grey Area No Unregistered Not specifically regulated. General pharma law applies. Vietnam Grey Area No Unregistered Not specifically regulated. Zambia Grey Area No Unregistered Not specifically regulated. No domestic market. Import without ZAMRA authorization illegal. Zimbabwe Grey Area No Unregistered Not specifically regulated. No domestic market. Import without MCAZ authorization illegal. Australia Prescription Yes Schedule 4 + Appendix D Item 5 Individually named in Schedule 4 + Appendix D since 1 June 2015. Captured by both individual entry AND class entry (GHRHs). Austria Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Belgium Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Czech Republic Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Denmark Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Finland Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. France Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Germany Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Greece Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Ireland Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Italy Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Netherlands Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. New Zealand Prescription Yes Unapproved (Rx Required) Prescription medicine. Not Medsafe approved. Norway Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Poland Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Portugal Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Spain Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Sweden Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. Switzerland Prescription Yes Unauthorized Medicine No EMA authorization. GHRH analog. WADA banned. Research-label available. United Arab Emirates Prescription Yes Clinic Prescribed Available at anti-aging clinics. Prescription required. China Banned No Unapproved Drug Unauthorized. No consumer access. Cuba Banned No State Controlled State pharmaceutical monopoly via CECMED/BioCubaFarma. No private purchase/import permitted. Saudi Arabia Banned No Unauthorized Unauthorized. Do not import. Singapore Banned No Unapproved Health Product Unapproved. Do not import.